Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267085 | 1.00 | CXCR2 (0.84) | CXCR2CX3CR1 | |
| SCHEMBL5433102 | 0.91 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL5235875 | 0.91 | CXCR2 (0.87) | CXCR2CX3CR1 | |
| SCHEMBL5232577 | 0.91 | CXCR2 (0.87) | CXCR2CX3CR1 | |
| SCHEMBL5237440 | 0.91 | CX3CR1 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL5237451 | 0.91 | CX3CR1 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL5265672 | 0.91 | CXCR2 (0.85) | CXCR2CX3CR1 | |
| SCHEMBL5265674 | 0.91 | CXCR2 (0.85) | CXCR2CX3CR1 | |
| SCHEMBL5232652 | 0.88 | CXCR2 (0.81) | CXCR2CX3CR1 | |
| SCHEMBL5232643 | 0.88 | CXCR2 (0.81) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067657-B2 | Thiazolopyrimidine derivatives and use thereof as antagonists of the CX3 CR1 receptor | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | claimed |
| US-20040106628-A1 | Novel use | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | claimed |
| EP-1377590-A1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3 CR1 RECEPTOR | AstraZeneca AB (SE) | 2004-01-07 | — | — | EP | claimed |
| WO-2002076990-A1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3 CR1 RECEPTOR | ASTRAZENECA AB (SE) | 2002-10-03 | — | — | WO | claimed |
| EP-1377590-B1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3CR1 RECEPTOR | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-7067657-B2 | Thiazolopyrimidine derivatives and use thereof as antagonists of the CX3 CR1 receptor | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20040106628-A1 | Novel use | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106628-A1 | Novel use | CX3CR1, CNR1, ARRB1 | CXCR2 24/4885CX3CR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.